A writer's account of losing most of her hearing describes a frightening medical event followed by disputes over hearing aids and treatment. It is credible testimony about one patient's experience, but it is not evidence that US emergency departments or insurers routinely produce the same outcome.
Deborah Copaken's essay was published by The Guardian on March 11, 2026. She wrote that the episode began in early July 2022, when she awoke during a Covid infection with almost no hearing. That chronology replaces the original article's incorrect suggestion that the case unfolded in March 2026.
The Essay Documents One Patient's Course
Copaken reported that an emergency-room clinician prescribed steroids and that later testing identified both conductive and sudden sensorineural hearing loss. She also described pre-existing mild hearing damage associated with an explosion she had covered as a journalist.
According to her account, UnitedHealthcare denied coverage for hearing aids costing about $7,000 and for balloon dilation of the Eustachian tubes. She wrote that she appealed twice, eventually changed insurers and then obtained the procedure and hearing aids. The Guardian said UnitedHealthcare did not respond to its request for comment.
Those details should remain attributed to the writer. The essay provides no comparison group, claims data or representative sample from which to calculate denial rates, treatment delays or outcomes across the country.
Sudden Sensorineural Loss Requires Prompt Assessment
The US National Institute on Deafness and Other Communication Disorders describes sudden sensorineural hearing loss as a medical emergency. It often affects one ear and can be mistaken for congestion, earwax or an allergy. The institute advises prompt medical attention rather than waiting for the problem to resolve.
The American Academy of Otolaryngology–Head and Neck Surgery guideline says clinicians should first distinguish sensorineural loss from conductive loss. It recommends audiometry as soon as possible and within 14 days of symptom onset. The guideline says corticosteroids may be offered within two weeks, while injections through the eardrum should be offered as salvage therapy for incomplete recovery two to six weeks after onset.
These are timing recommendations, not a guarantee of restored hearing. NIDCD says roughly half of affected people recover some or all hearing spontaneously, usually within one or two weeks, while delayed treatment is less likely to reverse permanent loss. Individual prognosis depends on factors that an online account cannot determine.
Coverage Gaps Are Real but Need Precise Evidence
Copaken's reported denials illustrate how cost and coverage can complicate recovery. They do not prove that all private insurers use the same rules or that every denial is clinically unjustified; those conclusions would require policy documents and broader outcome data.
A separate, documented gap exists in traditional Medicare. The Centers for Medicare & Medicaid Services says Medicare Part B covers diagnostic hearing and balance examinations when statutory conditions are met, but does not cover hearing aids or examinations for fitting them. Medicare also does not cover therapeutic auditory rehabilitation.
That distinction matters: access to diagnosis does not necessarily include the devices and rehabilitation a person may need afterward. It supports scrutiny of benefit design, but it cannot be used as a substitute for evidence about Copaken's private plan.
A Human Account Is a Warning, Not a National Dataset
The essay's strongest contribution is showing what sudden hearing loss, uncertainty and large out-of-pocket costs can feel like. Its weakness as policy evidence is equally clear. A single account cannot establish the frequency of delayed referrals, improper denials, job loss or social isolation among Americans with hearing loss.
The defensible indictment is narrower and harder to dismiss: official guidance demands fast assessment, while documented insurance exclusions can leave diagnosis and functional recovery on opposite sides of a coverage line. Policymakers should measure how often that divide delays treatment or blocks hearing support. Until those data exist, turning one person's ordeal into national statistics would repeat the evidentiary failure the story is supposed to expose.